1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting...
-
Upload
jeffrey-freeman -
Category
Documents
-
view
214 -
download
0
Transcript of 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting...
![Page 1: 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.](https://reader036.fdocuments.in/reader036/viewer/2022082820/56649f395503460f94c56882/html5/thumbnails/1.jpg)
1
One Year Post-Exclusivity Adverse Event Review:
Meloxicam
Pediatric Advisory Committee Meeting November 16, 2006
Hari Cheryl Sachs, MD, FAAPMedical OfficerPediatric and Maternal Health StaffOffice of New DrugsCenter for Drug Evaluation and Research Food and Drug Administration
![Page 2: 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.](https://reader036.fdocuments.in/reader036/viewer/2022082820/56649f395503460f94c56882/html5/thumbnails/2.jpg)
2
Background Drug Information
• Drug: Mobic® (meloxicam)
• Therapeutic Category: Nonsteroidal anti-inflammatory
• Sponsor: Boehringer Ingelheim
• Original Market Approval: April 13, 2000
• Pediatric Exclusivity Granted: April 15, 2005
• Mechanism of Action: related to prostaglandin synthetase (cyclo-oxygenase) inhibition
![Page 3: 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.](https://reader036.fdocuments.in/reader036/viewer/2022082820/56649f395503460f94c56882/html5/thumbnails/3.jpg)
3
Background Drug Information
• Indication: relief of the signs and symptoms of:– osteoarthritis and rheumatoid arthritis (adults)– Pauciarticular or polyarticular course Juvenile
Rheumatoid Arthritis (children > 2 years)
• Dosage:– Adults: 7.5 to 15 mg once daily– Children: 0.125 mg/kg (max 7.5 mg) once daily
![Page 4: 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.](https://reader036.fdocuments.in/reader036/viewer/2022082820/56649f395503460f94c56882/html5/thumbnails/4.jpg)
4
Drug Use Trends (Outpatient Settings): Meloxicam
• Dispensed retail prescriptions for group of 9 NSAIDs (including meloxicam) decreased by 21 %1
– 84.7 million (May 2004 to Apr 2005) to 66.9 million (May 2005 to Apr 2006)
– Valdecoxib and rofecoxib withdrawn (Sept 2004 and April 2005 respectively)
– Retail prescriptions (but not over-the-counter products sales) of ibuprofen and naproxen included
• Dispensed prescriptions for meloxicam ranked fourth among the 9 nonsteroidal anti-inflammatory drugs1
– Estimated 7.4 million (11 %) (May 2005 to April 2006)• Pediatric use 0.3 % (approximately 21,000 prescriptions from May
2005 to April 2006)2
– Diagnosis: Ankle sprains, juvenile osteochondrosis31Verispan LLC, Vector One®: National (VONA). Data extracted June 2006.
Nine NSAIDs: celecoxib, ibuprofen, indomethacin, meloxicam, naproxen, oxaprozin, rofecoxib, tolmetin, and valdecoxib.2Verispan LLC, Vector One®: National (VONA). Data extracted June 20063Verispan LLC, Vector One®: Physician Drug & Diagnosis Audit. Data extracted June 2006
![Page 5: 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.](https://reader036.fdocuments.in/reader036/viewer/2022082820/56649f395503460f94c56882/html5/thumbnails/5.jpg)
5
Pediatric Exclusivity Labeling Changes: Meloxicam
Clinical Pharmacology: Special Populations- PediatricGeneral trend lower exposure in younger patients (2 to 6
years), compared to older patients (7 to 16 years)Half-life slightly longer in younger patientsWeight (not age) predictor of clearance
Clinical TrialsTwo 12-week, double-blind, parallel arm, active-
controlled trials are describedIndications
Indicated for relief of signs and symptoms of JRA (> 2 years)
![Page 6: 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.](https://reader036.fdocuments.in/reader036/viewer/2022082820/56649f395503460f94c56882/html5/thumbnails/6.jpg)
6
Pediatric Exclusivity Labeling Changes: Meloxicam
Precautions: Pediatric UseSafety and effectiveness for pediatric JRA patients (2 to
17 years) evaluated in 3 clinical trialsAdverse Reactions
Safety database: 378 patients dosed 0.125 to 0.375 mg/kg/day up to 24 weeks (efficacy) and 1 year (efficacy and pk studies)
Although adverse events similar between adults and children, abdominal pain, vomiting, diarrhea, headache and pyrexia more common in children
Dosage and AdministrationWeight based dosing is included
![Page 7: 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.](https://reader036.fdocuments.in/reader036/viewer/2022082820/56649f395503460f94c56882/html5/thumbnails/7.jpg)
7
Summary: Meloxicam• No pediatric AEs identified during one-year
exclusivity period• Since approval, 5 pediatric AEs- either labeled
events or confounded, with exception of one case of Bell’s palsy
• This completes the one-year post-exclusivity AE reporting as mandated by BPCA
• FDA recommends routine monitoring of meloxicam for AEs in all populations.
• Does the Advisory Committee concur?
![Page 8: 1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.](https://reader036.fdocuments.in/reader036/viewer/2022082820/56649f395503460f94c56882/html5/thumbnails/8.jpg)
8
Acknowledgements
OSE
Gita Akhavan-Toyserkani
Andrea Feight
Laura Governale
Solomon Iyasu
Rosemary Johann-Liang
Carol Pamer
DAARPSharon HertzTatiana OussovaJeff Siegel
PMHSLisa MathisKristin PhucasJean Temeck